ReNerve Limited (ASX: ReNerve) has received market registration (approval) in Malaysia for its NervAlign® Nerve Cuff.
The approval adds Malaysia to the Company’s list of Asia-Pacific clearances, alongside Hong Kong and Thailand. Malaysia has a population of 35 million and is a key market within ReNerve’s broader regional strategy, with many hospitals operating across multiple countries. The nerve repair market across Asia-Pacific is estimated to be worth around USD$100 million in 2026.
"Our approval in Malaysia is part of our regional strategy and is another major piece of validation, showing the strong clinical data package and clear benefit patients receive when the ReNerve Nerve Cuff is used in peripheral nerve repairs. We look forward to growing our presence in Malaysia and beyond that within the Asia-Pacific region." said Dr Julian Chick, CEO of ReNerve.
NervAlign® Nerve Cuff is designed to support peripheral nerve regeneration and recovery, providing clinicians with a precise option for use following traumatic injuries, surgical procedures, and other conditions affecting peripheral nerves.
About ReNerve
ReNerve is a medical device company developing products for peripheral nerve injury (PNI) repair. The company was founded by a neurosurgeon and medtech researchers and is focused on ready-to-use solutions designed to support peripheral nerve surgery.
ReNerve’s lead product is the FDA-cleared NervAlign® Nerve Cuff. The company recently reported results from a clinical study comparing standard of care nerve repairs with repairs protected using the NervAlign® Nerve Cuff. According to ReNerve, post-surgical pain scores in the NervAlign® cohort fell from 7.1 to 0.4, compared with a reduction from 7.1 to 3.3 in the standard of care cohort, which it described as a statistically significant improvement.
Product portfolio
ReNerve is developing a broader portfolio of nerve repair and adjacent tissue products, including:
- NervAlign® Nerve Cuff: a bioabsorbable protective wrap intended to be absorbed within 6 months of surgery.
- Deep dermal tissue product: a deep dermal product intended for use in reconstructive and cosmetic surgical procedures.
- Amniotic tissue product ranges: 3 amniotic tissue ranges intended to support wound healing.
- NervAlign® Nerve Conduit Range: a nerve conduit designed to support nerve growth over short gaps between nerve ends, incorporating eCOO technology.
- NervAlign® Nerve Guide Matrix: a customised, ready-to-use alternative to existing nerve grafts aimed at longer gaps and more severe nerve injuries, intended to avoid sural nerve harvesting.
- NervAlign® Bionic Nerve: a combination technology under development for complex nerve repair cases.
ReNerve launched its product range in 2022 and reported FY25 revenue growth of 53% to $271,000 in sales. The company has also cited estimates valuing the global nerve repair market at US$1.6 billion in 2024, with projections to reach US$6.2 billion by 2031.
Strategy
ReNerve’s stated focus is on developing products intended to improve the surgical environment for nerve repair and regeneration, with an emphasis on reducing complications and supporting recovery outcomes.